ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday

Key Points

• ACADIA will report Q1 2026 results after the market closes on Wednesday, May 6, 2026, with analysts forecasting $0.06 EPS and $281.80 million in revenue.
• In the prior quarter the company delivered a large surprise, reporting $1.60 EPS vs. a consensus of $0.12 and revenue of $298.0 million, up 9.4% year‑over‑year.
• Analysts maintain a generally positive view (consensus “Moderate Buy” with an average price target of $31.21), while insiders sold roughly 10,689 shares last quarter, indicating some executive-level trimming.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) is projected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.06 per share and revenue of $281.8010 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The business had revenue of $298.00 million for the quarter, compared to analysts' expectations of $292.54 million. During the same period in the prior year, the firm earned $0.86 EPS. The business's quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts expect ACADIA Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $22.67 on Wednesday. ACADIA Pharmaceuticals has a 1 year low of $14.18 and a 1 year high of $28.35. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of 9.90, a PEG ratio of 23.31 and a beta of 0.83. The business has a fifty day moving average of $22.25 and a 200-day moving average of $23.85.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Royal Bank Of Canada decreased their price target on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an "outperform" rating for the company in a research note on Thursday, February 26th. Oppenheimer reissued a "market perform" rating on shares of ACADIA Pharmaceuticals in a research note on Friday, February 6th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 3rd. Mizuho upgraded ACADIA Pharmaceuticals from a "neutral" rating to an "outperform" rating and lifted their price target for the company from $29.00 to $35.00 in a research report on Monday, February 23rd. Finally, TD Cowen lifted their price target on ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.21.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 2,709 shares of the firm's stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $22.20, for a total transaction of $60,139.80. Following the completion of the sale, the executive vice president directly owned 62,836 shares of the company's stock, valued at $1,394,959.20. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jennifer J. Rhodes sold 6,950 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the sale, the executive vice president directly owned 7,609 shares of the company's stock, valued at approximately $177,898.42. This represents a 47.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 10,689 shares of company stock worth $245,497. 28.30% of the stock is owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Cetera Investment Advisers boosted its stake in shares of ACADIA Pharmaceuticals by 2.7% during the 4th quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 436 shares in the last quarter. J.W. Cole Advisors Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 2.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company's stock worth $551,000 after acquiring an additional 501 shares in the last quarter. Vise Technologies Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 4.0% during the 3rd quarter. Vise Technologies Inc. now owns 15,367 shares of the biopharmaceutical company's stock worth $328,000 after acquiring an additional 585 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of ACADIA Pharmaceuticals by 0.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company's stock worth $1,964,000 after acquiring an additional 626 shares in the last quarter. Finally, Advyzon Investment Management LLC boosted its stake in shares of ACADIA Pharmaceuticals by 7.4% during the 4th quarter. Advyzon Investment Management LLC now owns 11,612 shares of the biopharmaceutical company's stock worth $310,000 after acquiring an additional 798 shares in the last quarter. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.